198 related articles for article (PubMed ID: 37524451)
1. Imeglimin prevents visceral hypersensitivity and colonic hyperpermeability in irritable bowel syndrome rat model.
Nozu T; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
J Pharmacol Sci; 2023 Sep; 153(1):26-30. PubMed ID: 37524451
[TBL] [Abstract][Full Text] [Related]
2. Phlorizin attenuates visceral hypersensitivity and colonic hyperpermeability in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
Biomed Pharmacother; 2021 Jul; 139():111649. PubMed ID: 33957565
[TBL] [Abstract][Full Text] [Related]
3. Imipramine improves visceral sensation and gut barrier in rat models of irritable bowel syndrome.
Nozu T; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
Eur J Pharmacol; 2020 Nov; 887():173565. PubMed ID: 32946869
[TBL] [Abstract][Full Text] [Related]
4. Peripheral apelin mediates visceral hypersensitivity and impaired gut barrier in a rat irritable bowel syndrome model.
Nozu T; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
Neuropeptides; 2022 Aug; 94():102248. PubMed ID: 35526468
[TBL] [Abstract][Full Text] [Related]
5. Tranilast alleviates visceral hypersensitivity and colonic hyperpermeability by suppressing NLRP3 inflammasome activation in irritable bowel syndrome rat models.
Nozu T; Arie H; Miyagishi S; Ishioh M; Takakusaki K; Okumura T
Int Immunopharmacol; 2024 May; 133():112099. PubMed ID: 38643709
[TBL] [Abstract][Full Text] [Related]
6. EMA401, an angiotensin II type 2 receptor antagonist blocks visceral hypersensitivity and colonic hyperpermeability in rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Ishioh M; Takakusaki K; Okumura T
J Pharmacol Sci; 2021 Jul; 146(3):121-124. PubMed ID: 34030794
[TBL] [Abstract][Full Text] [Related]
7. Losartan improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
Neurogastroenterol Motil; 2020 Jun; 32(6):e13819. PubMed ID: 32056324
[TBL] [Abstract][Full Text] [Related]
8. Butyrate inhibits visceral allodynia and colonic hyperpermeability in rat models of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
Sci Rep; 2019 Dec; 9(1):19603. PubMed ID: 31862976
[TBL] [Abstract][Full Text] [Related]
9. Dehydroepiandrosterone sulfate improves visceral sensation and gut barrier in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
Eur J Pharmacol; 2019 Jun; 852():198-206. PubMed ID: 30935894
[TBL] [Abstract][Full Text] [Related]
10. Altered colonic sensory and barrier functions by CRF: roles of TLR4 and IL-1.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Endocrinol; 2018 Nov; 239(2):241-252. PubMed ID: 30139928
[TBL] [Abstract][Full Text] [Related]
11. Visceral hypersensitivity in irritable bowel syndrome.
Kanazawa M; Hongo M; Fukudo S
J Gastroenterol Hepatol; 2011 Apr; 26 Suppl 3():119-21. PubMed ID: 21443723
[TBL] [Abstract][Full Text] [Related]
12. Environmental enrichment prevents stress-induced epigenetic changes in the expression of glucocorticoid receptor and corticotrophin releasing hormone in the central nucleus of the amygdala to inhibit visceral hypersensitivity.
Orock A; Louwies T; Ligon CO; Mohammadi E; Greenwood-Van Meerveld B
Exp Neurol; 2021 Nov; 345():113841. PubMed ID: 34390704
[TBL] [Abstract][Full Text] [Related]
13. Corticotropin-releasing factor receptor type 1 and type 2 interaction in irritable bowel syndrome.
Nozu T; Okumura T
J Gastroenterol; 2015 Aug; 50(8):819-30. PubMed ID: 25962711
[TBL] [Abstract][Full Text] [Related]
14. Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction.
Vicario M; Alonso C; Guilarte M; Serra J; Martínez C; González-Castro AM; Lobo B; Antolín M; Andreu AL; García-Arumí E; Casellas M; Saperas E; Malagelada JR; Azpiroz F; Santos J
Psychoneuroendocrinology; 2012 Jan; 37(1):65-77. PubMed ID: 21641728
[TBL] [Abstract][Full Text] [Related]
15. Corticotropin-releasing factor receptor 1 (CRF-R1) antagonists: Promising agents to prevent visceral hypersensitivity in irritable bowel syndrome.
Lv Y; Wen J; Fang Y; Zhang H; Zhang J
Peptides; 2022 Jan; 147():170705. PubMed ID: 34822913
[TBL] [Abstract][Full Text] [Related]
16. Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Pharmacol Sci; 2019 Jan; 139(1):46-49. PubMed ID: 30522964
[TBL] [Abstract][Full Text] [Related]
17. Lipopolysaccharide induces visceral hypersensitivity: role of interleukin-1, interleukin-6, and peripheral corticotropin-releasing factor in rats.
Nozu T; Miyagishi S; Nozu R; Takakusaki K; Okumura T
J Gastroenterol; 2017 Jan; 52(1):72-80. PubMed ID: 27075754
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological Commonality Between Irritable Bowel Syndrome and Metabolic Syndrome: Role of Corticotropin-releasing Factor-Toll-like Receptor 4-Proinflammatory Cytokine Signaling.
Nozu T; Okumura T
J Neurogastroenterol Motil; 2022 Apr; 28(2):173-184. PubMed ID: 35189599
[TBL] [Abstract][Full Text] [Related]
19. Visceral hypersensitivity induced by mild traumatic brain injury via the corticotropin-releasing hormone receptor: An animal model.
Mizoguchi A; Higashiyama M; Wada A; Nishimura H; Tomioka A; Ito S; Tanemoto R; Nishii S; Inaba K; Sugihara N; Hanawa Y; Horiuchi K; Okada Y; Kurihara C; Akita Y; Narimatu K; Komoto S; Tomita K; Kawauchi S; Sato S; Hokari R
Neurogastroenterol Motil; 2023 Oct; 35(10):e14634. PubMed ID: 37357384
[TBL] [Abstract][Full Text] [Related]
20. Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats.
Nozu T; Miyagishi S; Kumei S; Nozu R; Takakusaki K; Okumura T
J Gastroenterol Hepatol; 2019 Jan; 34(1):186-193. PubMed ID: 29966173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
